tbuckley/cabot-search huggingface dataset:
ACCESSORY RENAL ARTERIES ARE MARKEDLY MORE PREVALENT IN PATIENTS WITH RESISTANT HYPERTENSION UNDERGOING RENAL DENERVATION THAN IN NORMOTENSIVE SUBJECTS: EVIDENCE FOR A CAUSAL RELATIONSHIP?
Authors: Paige Vonachen, Jason Hamann, Thomas Houghland, Kristi Rosenthal, John Lesser, Robert Schwartz
Journal: Journal of the American College of Cardiology (2015)
Ipsilateral Lymph Node Uptake of Tc-99m HMPAO WBC in Two Men With Foot Infections
Authors: JOHN A. VENTO, MOZAFAREDDIN K. KARIMEDDINI, RICHARD P. SPENCER
Journal: Clinical Nuclear Medicine (1996)

Two men with osseous infections in a distal extremity were noted to have uptake of Tc-99m HMPAO autologous WBC not only in the affected site, but in the ipsilateral lymph nodes in the groin as well (and in one case there was further inward extension). In addition to reports on occasional lymph node uptake of In-111 oxine WBC, the phenomenon can occur with WBC carrying the Tc-99m HMPAO label.
WHO NOSE? TRANSNASAL GASTROSCOPY MIGHT BE BEST–A PILOT FEASIBILITY, SAFETY AND ACCEPTABILITY COMPARATIVE STUDY
Authors: B Hall, G Holleran, S Lawson, J Regan, M Murphy, B McMahon, D McNamara
Journal: Gut (2013)

<h3>Introduction</h3> Standard upper endoscopy (SE) is an integral aspect of diagnostic and therapeutic gastroenterology. Patients frequently request conscious sedation as they perceive the procedure may cause pain or discomfort. Administration of sedation incurs additional costs and risks. Transnasal endoscopy (TNE) has the potential to overcome these issues as it does not induce the pharyngeal reflex and does not require conscious sedation. <h3>Aims/Background</h3> To compare the feasibility, safety and tolerance of TNE as a viable alternative to SE. <h3>Method</h3> Patients scheduled for routine upper endoscopy were prospectively recruited and invited to undergo a non-sedated TNE procedure. A further group of patients scheduled for non-sedated SE were invited to participate as a control group. The SE procedures were performed using standard protocol with topical application of oral Xylocaine 10–30 mgs and a standard size Olympus gastroscope. All TNE procedures were performed using a Pentax EG-1690K 5.4 mm transnasal gastroscope via the nasal floor following application of instillagel nasally and topical oral Xylocaine 10–30 mgs. Post procedure fasting (1 hour) and recovery advice was the same for both groups. The indication, duration and complications of each procedure were recorded. A visual analogue scale was used to assess overall patient tolerance and tolerance for each of the following parameters; pain, gagging, choking and anxiety graded on a 0-10 scale. All results were expressed as a mean and compared with a student T-test using SPSS 19. A P value 0f &lt;0.05 was considered significant. <h3>Results</h3> To date, 22 patients, 12 men, mean age 56 years (range 35–74) have been enrolled, 12 in the TNE group and 10 in the SE group. Indications were GORD (n=7, 31%), dysphagia (n=6, 27%), epigastric pain (n=5, 22%) and nausea (n=4, 18%). All procedures were completed with intubation to D2. There were no complications. There were no differences in mean procedure duration for either TNE or SE (TNE 9.3 mins; SE 9 mins). Both procedures were well tolerated with VAS scores of 2.3 and 3.4 for TNE and SE respectively (p&lt;0.03). However, there was a significant advantage for TNE versus SE for choking on intubation (3.2 vs 5.4, p&lt;0.03 95% CI 1.4–4.9), gagging on intubation (2.4 vs 5.1, p&lt;0.03 95% CI 1.2–3.8) and gagging during the procedure (1.8 vs 4.1=, p&lt;0.03 CI 1.2–2.9). <h3>Conclusion</h3> Our pilot study suggests that TNE may be useful as a tool in diagnostic upper endoscopy. It is reliable, safe and better tolerated by patients compared to SE. Potential added advantages included improved views, reduced length of stay and fewer complications. Ongoing recruitment will be required to address this.
Abstract P3-06-25: PTEN mRNA positivity using <i>in situ</i> measurements is associated with better outcome in Tamoxifen treated breast cancer patients.
Authors: KA Schalper, K Li, DL Rimm
Journal: Cancer Research (2012)

Abstract Background: Aberrant phosphatidylinositol 3-kinase (PI3K) pathway signaling occurs in a high proportion of human breast cancers and is involved in carcinogenesis, tumor progression and resistance to targeted therapies. Reduced levels of the tumor suppressor PTEN has been associated with PI3K pathway activation and is observed in ∼40% of breast carcinomas. PTEN levels have traditionally been determined in breast tumors by qualitative immunohistochemistry (IHC) and its prognostic and/or predictive value has not been clearly established. We used a novel method of quantitative in situ measurements of PTEN mRNA and protein to determine their possible prognostic and predictive value in breast cancer. Materials and methods: PTEN mRNA and protein were measured on formalin fixed paraffin embedded (FFPE) cell lines and tumor samples on tissue microarrays (TMAs) representing a retrospective cohort of 404 breast cancer cases collected from the Yale Pathology archives between 1975 and 2005. The RNAscope paired-primer method was used for PTEN mRNA in situ hybridization (ISH), with Ubiquitin C and DapB ISH probes used as positive and negative controls for each run. PTEN protein measurements were performed with monoclonal antibody 138G6 (Cell Signaling Technology). Both mRNA and protein were measured using the AQUA method of quantitative immunofluorescence. Results: Both PTEN mRNA ISH signal and protein were highly reproducible in FFPE tissues and cell lines. PTEN mRNA levels were lower in cell lines with known PTEN downregulation. In breast carcinoma samples, PTEN mRNA scores showed a positive non-linear association with protein levels. Neither PTEN mRNA nor protein showed prognostic value. However, high PTEN mRNA expression using a visually defined cutoff was associated with better outcome in a subset of Tamoxifen treated breast cancer patients. Conclusion: Initial data suggests that PTEN mRNA expression may be predictive of favorable response to endocrine therapy in breast carcinomas. However, validation in larger independent cohorts is required. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-06-25.
CBIO-03ALTERNATIVE SPLICING IN GLIOBLASTOMA MULTIFORME: CHARACTERIZATION OF Baf45d ABERRANT SPLICING IN THE PATHOGENESIS OF GLIOBLASTOMA
Authors: Guillermo Aldave, Marisol Gonzalez Huarriz, Enric Xipell, Roeland Verhaak, Sonia Tejada-Solís, Ricardo Díez-Valle, Arlet Acanda de la Rocha, Naiara Martinez-Vélez, Marta Alonso
Journal: Neuro-Oncology (2015)

We performed, for the first time, an alternative splicing global analyses (AS) in Glioblastoma (GBM) using specific splicing arrays with paired samples (tumor/non tumor). We identified 51 genes with a significantly different AS and we chose BAF45d as one of the best candidates. BAF45d AS occurs by the exclusion of exon 7 (exon 6a). This exclusion results in a Zinc finger protein domain with the ability to bind specific DNA sequences. The predominant isoform in GBM is one that presents the exclusion of exon 6a (BAF45d-T) and therefore it harbours the zinc finger domain suggesting a possible role in transcription regulation. The inhibition of BAF45d-T in vitro results in a decrease in cell proliferation, in the capacity to self-renew and in the downregulation of markers related with an undifferentiated phenotype. In this line of thinking, we demonstrated that BAF45d-T isoform is present in murine neural progenitor and its expression is reduced during the differentiation toward mature neurons. The inhibition of BAF45d in vivo increases significantly animal survival in a GBM orthotopic model. Moreover, our work revealed that BAF45d splicing was mediated by PTBP1. Interestingly, we also found that BAF45d regulated positively the expression of PTBP1, uncovering a link between splicing regulation and chromatin remodelling. In summary, our results suggest that the AS of BAF45d AS participates in the GBM pathogenesis through the maintenance of an undifferentiated cellular state. In addition, our data suggest that alternative splicing is a mechanism that could be central to GBM development.
Floating Gallbladder: A Questionable Prelude to Torsion
Authors: K P Lyons, S Challa, D Abrahm, B M Kennelly
Journal: Clinical Nuclear Medicine (2000)

A 55-year-old woman had recurrent bouts of low substernal and epigastric pain radiating into the interscapular region. A hepatobiliary scan initially showed what was believed to be a dilated common bile duct and nonvisualization of the gallbladder. A delayed image obtained after having the patient move about revealed the presence of a filled gallbladder and normal common bile duct. The combination of recurrent pain with this scintigraphic picture may be representative of a floating gallbladder or an incomplete torsion with spontaneous detorsion. This case is presented to describe the scintigraphic appearance of a mobile gallbladder that may be prone to volvulus and to emphasize the importance of obtaining decubitus or oblique views at the end of a hepatobiliary study in selected cases of unusual findings.
Bleeding Time after Aspirin in Disorders of Intrinsic Clotting
Authors: M. M. Kaneshiro, C. H. Mielke, C. K. Kasper, S. I. Rapaport
Journal: New England Journal of Medicine (1969)

The Ivy bleeding times before and two hours after 1 gm of aspirin in 14 patients with mild hemophilia A, 2 with mild hemophilia B, 3 with PTA deficiency, and 3 with established or suspected von Willebrand's disease (despite a normal bleeding time) did not differ significantly from those found earlier in normal controls. Mean bleeding times before aspirin were normal in 11 patients with severe hemophilia A and eight with severe hemophilia B. Four patients in each group had profoundly prolonged bleeding times after aspirin. Seven patients eventually required transfusion to stop the bleeding. The combination of aspirin and the severe clotting defect "paralyzed" the formation of the platelet aggregates that stop bleeding in the bleeding-time test, illustrating the potential therapeutic hazard of aspirin in some patients with severe hemophilia.
AB0299 Association of basal level antibodies to modified citrullinated vimentin (anti-mcv) with joint destruction in rheumatoid arthritis (ra) patients during the tocilizumab (tcz) therapy
Authors: A. S. Avdeeva, E. N. Alexandrova, A. V. Smirnov, A. A. Novikov, M. V. Cherkasova, E. Y. Panasyuk, E. L. Nasonov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> RA- is a chronic inflammatory disease mediated by the production of proinflammatory cytokines, which leads to the destruction of bone and cartilage tissue in multiple joints. TCZ - humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody is effective and safe drug for the treatment of RA, prevents progressive joint destruction and causes decrease biochemical markers bone and cartilage degradation. <h3>Objectives</h3> To mark the impact of the TCZ therapy on bone destruction and the level of MMP3 in RA patients (pts). <h3>Methods</h3> Data were obtained from the first Russian open-label, Phase IV, multicenter 24 week study of the efficacy and safety of TCZ in RA. 42 pts with RA (32 woman, mean age 50,5; 43,0-55,0 years, mean disease duration 56,5; 23,0-81,0 months, mean DAS 28 6,4; 5,8-7,05) received 6 intravenous TCZ infusions (8 mg/kg) every 4 weeks, in combination with DMARDs and glucocorticoids. Erythrocyte sedimentation rate – ESR (mm/hr) was determined by Westergren method; antibodies to modified citrullinated vimentin – anti-MCV (U/ml) and matrix metalloproteinase -MMP 3 (ng/ml) were tested using ELISA. Radiographs of the hands and feet were performed at baseline and in 48 weeks. Damage was quantifi by using van der Heijde-modified Sharp scores. Radiographic non-progression was defined as a change in total modified Sharp score (mTSS) ≤0. <h3>Results</h3> The baseline mTSS [Me (interquartile range)] was 78 (46-122), erosion score – 10,5 (2-35), by 48-th week of treatment: the mTSS - 80 (44-130), the erosion score 13,5 (1,5-34), radiographic progression was observed in 9 pts (22,5%). All pts were divided into two groups by the level of anti-MCV before the therapy. RA pts, who had high positive basal level anti-MCV observed a lower incidence of radiographic progression (20%) and a significant decrease in MMP 3, compared with anti-MCV - negative / low positive pts (50% p = 0,05) (Table 1). <h3>Conclusions</h3> Anti-MCV high positive pts respond better to therapy TCZ (decline of level of MMP-3 and less percent of the radiographic progression) compared with anti-MCV negative/ low positive pts. <h3>Disclosure of Interest</h3> None Declared
Le brossage biliaire per-endoscopique suffit souvent en 2011 à poser le diagnostic de malignité d'une sténose biliaire
Authors: P Ponsot, F Maire, A Aubert, M Felce, O Hentic, P Hammel, P Lévy, P Ruszniewski, M Fabre
Journal: Endoscopy (2012)

Le brossage biliaire per-endoscopique affirme le diagnostic de malignité d'une sténose biliaire, mais avec une faible sensibilité. Le but de ce travail était d'évaluer si une technique standardisée de brossage, de recueil et d'analyse des prélèvements permettait d'améliorer la sensibilité de cette technique pour le diagnostic de malignité d'une sténose biliaire.
Estrogen Receptor and Peroxidase Activity in Epithelial Ovarian Carcinomas&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN4"&gt;4&lt;/xref&gt;
Authors: John A. Holt, C. Richard Lyttle, Margaret A. Lorincz, Scott D. Stern, Michael F. Press, Arthur L. Herbst
Journal: JNCI Journal of the National Cancer Institute (1981)

The endocrine biology of cancers originating from the ovarian epithelium was examined with respect to three sequential indicators for estrogen action: available estrogen receptor in the cytosol, total extractable estrogen receptor from the nucleus, and endogenous tissue peroxidase--a putative postnuclear marker for estrogen-induced growth in uteri of laboratory animals and in some mammary tumor models. Cancers of human ovarian epithelium were distinguished from other ovarian tumors by a higher incidence of detectable (greater than 50 fmol/g tissue wet wt) estrogen receptor in the cytosol (P less than 0.001). Approximately one-half (14/29) of the ovarian adenocarcinoma specimens had greater than 500 fmol available estrogen receptor/g tissue wet weight in their cytosols when assayed by a 2-hour incubation with 17 beta-[2,4,6,7-3H(N)]estradiol followed by treatment with dextran-coated charcoal. With a single exception, ovarian adenomas and nondiseased specimens of premenopausal and postmenopausal ovaries (n = 24) contained less than 500 fmol available estrogen receptor/g tissue wet weight in their cytosols. With respect to extractable estrogen receptor in the nucleus, 11/14 primary and 3/9 metastatic ovarian adenocarcinomas had greater than 50 fmol/g wet weight, as assayed by exchange at 30 degrees C for 5 hours after adsorption of the extracted receptor to hydroxylapatite. Endogenous peroxidase activity, measured in vitro by guaiacol oxidation, occurred in substantially higher amounts in the primary ovarian adenocarcinomas than in benign tumors and control ovaries and could be demonstrated within ovarian adenocarcinoma cells by electron microscopy.
Endoscopic ablation of Barrett's neoplasia with a new focal radiofrequency device: initial experience with the Halo60
Authors: B. Allen, N. Kapoor, R. Willert, H. McEwan, G. Fullarton, I. Penman
Journal: Endoscopy (2012)

Radiofrequency ablation (RFA) is an accepted treatment for the eradication of dysplastic Barrett’s esophagus (DBE) and residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma. Circumferential balloon-based and focal catheter-based RFA devices are currently used (the Halo<sup>360</sup> and Halo<sup>90</sup>). However, a new smaller focal ablation device (the Halo<sup>60</sup>) has been developed, which may be of benefit in patients with short tongues of Barrett’s neoplasia, small residual islands, difficult anatomy, or strictures. We report the first use of this device in 17 patients with either DBE or residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma.
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma
Authors: M. Battistella, A. Janin, F. Jean-Louis, C. Collomb, C. Leboeuf, H. Sicard, C. Bonnafous, A. Dujardin, C. Ram-Wolff, M.E. Kadin, A. Bensussan, M. Bagot, L. Michel
Journal: British Journal of Dermatology (2016)

KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome. Anti-KIR3DL2 targeted antibody therapy has shown potent activity in preclinical models for these diseases.To examine the expression of KIR3DL2 and its potential use as a therapeutic target in patients with primary cutaneous anaplastic large-cell lymphoma (pcALCL), the most aggressive cutaneous CD30(+) lymphoproliferative disease.Samples from 11 patients with pcALCL and three CD30(+) lymphoproliferative disease cell lines - Mac1, Mac2a and Mac2b - were used in KIR3DL2 expression studies using immunohistochemistry, flow cytometry and reverse-transcriptase quantitative polymerase chain reaction. The effect of IPH4102, a monoclonal humanized IgG1 targeting KIR3DL2, was assessed by in vitro cytotoxicity assays against Mac1, Mac2a and Mac2b using allogeneic peripheral blood mononuclear cells as effectors.KIR3DL2 mRNA and protein were found in all human samples of pcALCL, and in the Mac2a and Mac2b cell lines. KIR3DL2 protein expression was present on 85·8 ± 14·0% of CD30(+) skin-infiltrating tumour cells. In vitro functional studies showed that KIR3DL2(+) Mac2a and Mac2b pcALCL lines are sensitive to antibody-derived cytotoxicity mediated by IPH4102, through activation of natural killer cells, in a concentration-dependent manner.pcALCL tumour cells express KIR3DL2, and we provide preclinical proof of concept for the use of IPH4102, a humanized anti-KIR3DL2 antibody, to treat patients with primary cutaneous CD30(+) ALCL.
Avoiding a Rash Diagnosis
Authors: Julie E. Reznicek, William J. Mason, Daniel R. Kaul, Sanjay Saint, Karen C. Bloch
Journal: New England Journal of Medicine (2011)

A 74-year-old man presented to the emergency department with confusion and lethargy. He had been in his usual state of health until 2 weeks earlier, when his wife noted a decrease in his activity level in association with an unsteady gait and multiple falls.
Abstract 2270: Design, synthesis, and functional characterization of new cycle-peptides inhibitors for C-X-C chemokine receptor-4 (CXCR4)
Authors: Stefania Scala, Luigi Portella, Maria Napolitano, Claudia Consales, Maria Neve Polimeno, Crescenzo D'Alterio, Giuseppe Palma, Claudio Arra, Rosamaria Vitale, Pietro Amodeo, Stefania De Luca, Luca Monfrecola, Giuseppe Castello
Journal: Cancer Research (2010)

Abstract Modulation of the axis CXCR4/CXCL12 affected primary tumor growth and secondary lesions development. Moreover, CXCR4 inhibition increases hematopoietic stem cell mobility in patients undergoing autologous transplantation for myeloma and non-Hodgkin lymphoma. Although several CXCR4 inhibitors were described neither one reached satisfactory efficacy, bioavailability and acceptable toxicity. To develop new CXCR4 inhibitors through a rationale design approach, comparative studies were undertaken evaluating the N-terminal structure of the ligand CXCL12 and v-MIP II, an inhibitory chemokine like produced by the herpes virus 8-Kaposi associated. A common amino acidic motif (RFF) was identified in both structures although in inverted orientation. Having as a core this small domain, a new library (20 units) of cycle-peptide molecules was generated. 20 units of cycle-peptide molecules were synthesized that consists of 5 and 7 amino-acid residues cycled by a S-S bridge designed to interact with the receptor CXCR4. The peptides were characterized for functionally CXCR4 interaction through: 1. inhibition of CXCR4 binding; 2. inhibition of migration CXCL12-induced; 3. inhibition of calcium release CXCL12-induced; 4. Inhibition of P-Erk CXCL12-induced. Four peptides were identified as CXCR4 inhibitors. These four CXCR4 inhibitory peptides were further evaluated for the in vivo efficacy through inhibition of metastasis formation. B16 mouse melanoma cells transfected with CXCR4 were injected in the vein tail in C57 Bl mice and peptide treatment followed for 10 days. Dramatic reduction in number and size of lung metastases were registered in mice peptides-treated. Moreover, xenograft of human renal cancer cells SN12C-EGFP were subcutaneously injected and systemic peptides treatment followed for 10 days. Statistically significant decrease in tumor growth was showed in peptides treated mice. Taken together the data define four new CXCR4 inhibitory peptides, designed through innovative strategy, effective in “in vivo” systems deserving further development. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2270.
SAT0427 How Effective a Modified Exercise Program on its Own or with Back School in Chronic Low Back Pain? A Randomized-Controlled Clinical Trial
Authors: D. Durmus, M. unal, O. Kuru
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Chronic low back pain (CLBP) is seen frequently in all societies of the world that causes significant loss of working days. Many treatment modalities have been proposed for its treatment. <h3>Objectives</h3> The aim of this trial is to search effectiveness of specifically adopted exercise programs on its own and with low back school on pain, disability, trunk and quadriceps muscle strength, walking performance, spinal mobility, quality of life (QOL), and depression in the patients with CLBP. <h3>Methods</h3> A total of 121 patients with definite CLBP were included in this study. The patients were randomized into two groups. Group 1 (<i>n =</i> 60) was given exercises only and accepted as the control group. Group 2 (<i>n =</i> 61) received back school program and exercises. The exercise treatment was performed 3 days a week, for 3 months. The pain (visual analog scale, VAS), disability (Oswestry Disability Questionnaire, ODQ), walking performance (6 minute walking test, 6MWT), depression (Beck Depression Inventory scores, BDI), and QOL (Short Form 36, SF-36) of all participants were evaluated. The trunk and knee muscle strength were measured with a handheld dynamometer. Patients were assessed at baseline (BT), at the end of treatment (AT), and at the six month follow-up (F). <h3>Results</h3> Statistically significant improvements were found between groups regarding all of the clinical parameters over time. Pain, disability, muscle strength, endurance, 6MWT, mobility, QOL, and depression of both groups also showed improvements AT. These improvements persisted at 6-months follow-ups (<i>P</i> &lt; 0.05). There were statistically significant differences between the groups for pain, disability, muscle strength, endurance, 6MWT, QOL, and depression regarding the change scores between AT–BT test and F–BT test (<i>P</i> &lt; 0.05). Group 2 fared better than group 1 except for mobility. <h3>Conclusions</h3> Exercise programs can be modified and used successfully in CLBP and this effect can be increased with addition of back school further. <h3>Disclosure of Interest</h3> None Declared